Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Implementation of Competency-Based Medical Education in Surgical Training: A Scoping Review.

Journal of surgical education·2026
Same author

Perimetric Outcomes of Melbourne Rapid Field Perimetry in Patients With Glaucoma: A Systematic Review and Meta-Analysis.

Journal of glaucoma·2026
Same author

Clinical validation of an HPV whole-genome sequencing assay for MRD detection in patients with HPV+ head and neck cancer treated with surgery.

Science translational medicine·2026
Same author

Locally-affiliated authorship in global eye health research conducted in Sub-Saharan Africa between 2003 and 2022.

Eye (London, England)·2026
Same author

Workplace Accommodations for Workers With Hearing Loss: A Scoping Review With Implications for the Health Setting.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·2026
Same author

Liquid Biopsy of HPV Cell-Free DNA Enables Blood-Based Early Detection and Molecular Stratification of HPV-Associated Cancer and Precancer Stages.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Jul 12, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.7K

circulating tumor DNA in the immediate post-operative setting.

Vasileios Efthymiou1, Natalia Queenan1, Markus Haas1

  • 1Department of Otolaryngology-Head and Neck Surgery Massachusetts Eye and Ear, Boston, Massachusetts.

Medrxiv : the Preprint Server for Health Sciences
|October 24, 2023
PubMed
Summary

Detecting circulating tumor DNA (ctDNA) within three days after surgery accurately predicts cancer recurrence. This early biomarker assessment aids in determining minimal residual disease, guiding treatment decisions.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

11.1K

Related Experiment Videos

Last Updated: Jul 12, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.7K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

11.1K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Biomarker Research

Background:

  • Circulating tumor DNA (ctDNA) is a validated real-time biomarker for solid tumors.
  • Current ctDNA research often overlooks immediate postoperative time points crucial for adjuvant treatment decisions.
  • This review focuses on the feasibility of using ctDNA in the early postoperative period.

Conclusions:

  • Detectable ctDNA within three days post-surgery is predictive of recurrence.
  • Early postoperative ctDNA assessment is feasible for minimal residual disease detection.
  • Further research with larger cohorts is needed to refine ctDNA kinetics and optimal timing across tumor types.